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ABSTRACT
Melanocortins (MCs) play an important role in feeding, metabolism, and energy expenditure.
While melanocortin receptor (MCR) mRNA has been found in the mesolimbic dopamine (DA)
pathway, the ability of melanocortins to regulate feeding and other behaviors through actions on
the mesolimbic DA system have not been examined. Short-hairpin RNAs (shRNAs) were
created targeting MC3R and MC4R and were tested via in vitro studies for their ability to
knockdown their target receptor. A total of three shRNAs were created targeting each receptor,
and each shRNA caused successful knockdown. These shRNAs are tools that can be used for
future in vivo studies to examine the various behavioral effects of melanocortins on the
mesolimbic DA pathway.
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INTRODUCTION
Today, it is estimated that 68% of adults and 32% of children in the United States are

considered overweight or obese (Ogden et al 2012a; 2012b; Flegal et al 2010). Obesity is shown
to have correlations with heart disease, hypertension, stroke, type II diabetes, sleep apnea,
various cancers, infertility, and overall decreased life expectancy (Haslam & James 2005).
Obesity and food intake are influenced by a variety of psychological factors such as food choice,
social interactions, and aesthetics as well as physiological factors such as energy stores,
endocrine signals, paracrine signals, and neuropeptides. It is debated how each of these factors
works to cause or cease feeding via peripheral and central control. Peripheral cues are an
important aspect of food intake control; however, the main focus of this paper will be within the
central nervous system.
1.1

The homeostatic pathway of the hypothalamus
Prior to the 1950s, scientists believed hunger was solely under gastrointestinal control;

however, the hypothalamus and brainstem gained recognition as major contributors in the role of
feeding (Kennedy 1953). Early studies describe the hypothalamus as having a main ‘feeding’
center in the lateral hypothalamus and a main ‘satiety’ center in the ventromedial hypothalamus
(Anand & Brobeck 1951; Teitelbaum & Stellar 1954; Mayer & Thomas 1967), though
subsequent research has demonstrated that multiple areas of the brain, including areas within the
hypothalamus play key roles in the regulation of feeding and body weight. One area of the
hypothalamus shown to play a key role in the regulation of food intake is the arcuate nucleus of
the hypothalamus (ARC). The ARC has a high number of hormonal and neuropeptide receptors
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and many of them affect feeding such as opioids, orexins, melanin-concentrating hormone,
galanin-like peptides, galanin, and many more.
One important family of ARC neuropeptides that play a key role in regulating feeding are
the melanocortins. The melanocortins are a family of neuropeptides produced by the
proopiomelanocortin gene or POMC. Once created the POMC neuropeptide is broken down
from its preprohormone precursor to physiologically active substances such as
adrenocorticoptropic hormone (ACTH), α, β, and γ melanocyte-stimulating hormone (MSH), and
β-endorphin (Mountjoy et al 1992; Palkovits et al 1987) as seen in Figure 1 (Cone 2006).

Figure 1. Breakdown of melanocortin neuropeptides from its original state as a
preprohormone
POMC preprohormone is broken down from its preprohormone precursor to N-terminal,
adrenocorticoptropic hormone (ACTH), and β-lipotropin (LPH) which are then broken down to
create α, β, and γ melanocyte-stimulating hormone (MSH), corticotrophin-like intermediate
peptide (CLIP), γ-LPH, and β-endorphin (Cone 2006).
The MSHs are commonly referred to as the melanocortins. α-MSH is considered to be the
most physiologically relevant melanocyte-stimulating hormone in the CNS because of its
anorexigenic effects (decreases feeding); however, β and γ-MSH also been shown to have some
physiological significance (Gantz et al 1999). Intraventricular injection of α-MSH is known to
cause decreased food intake, increase energy expenditure, and chronically can cause cachexia, or
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extreme weight loss and malnourishment (Panskepp et al 1976; Fan et al 1997). A second set of
neurons in the hypothalamus expresses agouti-related protein (AgRP), which is an endogenous
antagonist of melanocortin receptors. AgRP acutely increases food intake, decrease energy
expenditure, and chronically increases body weight (Fan et al 1997; Huszar et al 1997). AgRP is
an antagonist to the melanocortins (Corander et al 2011), but can also act as an inverse agonist.
This suggests that it not only blocks the receptor, but can cause the opposite effect, in this case,
increased feeding (Haskell-Luevano & Monck 2001; Nijenhuis et al 2001). ACTH is produced in
response to stress and has implications in grooming and sexual function. It is produced in the
pituitary gland and mainly affects melanocortin receptors at its site of production as well as the
adrenal cortex. β-endorphin is an endogenous opioid that has many functions, one being that it
stimulates food intake through its receptors in the ARC and other places (Appleyard et al 2003).
There are five known G-protein coupled receptors that react with MSHs, melanocortin-1
receptor (MC1R) through melanocortin-5 receptor (MC5R) (Griffon et al 1994; Labbe et al
1994). MC3R and MC4R are the only two receptors present in the central nervous system (CNS)
and therefore are the main focus of study in neurobiology (Mountjoy et al 1994; Roselli-Rehfuss
et al 1993; Gantz et al 1993; Chhaklani et al 1996). MC4R is considered the primary MCR
involved in body weight control because of its high binding affinity with α-MSH and resulting
strong physiological changes (Gantz et al 1993). MC4R plays a major role in energy homeostasis
via food consumption control, energy expenditure, changes in sympathetic nervous system
(SNS) activity. MC4R null mice are hyperphagic, gain weight, and develop insulin-resistance
induced diabetes (Gantz & Fong 2002; Sutton et al 2006; Huszar et al 1997; Garza et al 2008).
Melanocortin 4 deficiency is the largest monogenic cause for obesity in humans (Krude et al
1998; Farooqi et al 2000; Yaswen 1999). Though MC3R plays a role in body weight regulation,
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the exact role is less clear. MC3R is involved in energy homeostasis via the manipulation of
energy metabolism, or the fat-to-mass ratio. MC3R null mice do not increase food intake, but
have a higher fat to mass body ratio than its wild-type counterparts. Research suggests this is
caused by a change in metabolism due in large part to decreases in locomotor activity (Sutton et
al 2006; Butler et al 2000; Chen et al 2000). Although MC3R has binding affinity with α, β and,
γ-MSH, it has a lack of unique agonists/antagonists that exclusively bind to the MC3R which has
made studying its effects difficult. Many still question the importance of MC3R due to
confounding research (Lee et al 2008; Fan et al 1997). Recent papers, however, show that MC3R
does in fact effect feeding, but the mechanism is still unknown (Marks et al 2006; Irani et al
2011).
Among the many neuronal subtypes in the ARC, two populations of neurons have been
shown to play an important role in feeding, the first expressing proopiomelanocortin (POMC)
and a second set of neurons expressing agouti-related peptide (AgRP) and neuropeptide Y
(NPY). POMC neurons are potent anorexigenic stimulators while AgRP/NPY neurons are potent
orexigenic stimulators (increase feeding) (Huzsar et al 1997; Fan et al 1997; Bulter et al 2000).
Recent DREADD and optogenetic technologies have shown that stimulation of POMC neurons
decreases food intake and body weight in the presence of only melanocortins and no other
neuropeptide (Aponte et al 2011). Stimulation of the AgRP/NPY neurons acutely and
dramatically increases food intake, decrease energy expenditure, and chronically increases body
weight (Aponte et al 2011). Inhibition of AgRP neurons decreases food intake to below baseline
standards independent of melanocortin stimulation suggesting AgRP is both ‘necessary and
sufficient’ for feeding behavior (Krashes et al 2011). POMC and AgRP/NPY neurons share
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many of the same projections as seen in Figure 2 (Cone 2005). This allows these two opposing
systems to have control on each other.

Figure 2. Projections of POMC and AgRP neurons throughout the rat brain
POMC and AgRP neurons both project to the central nucleus of the amygdala, bed nucleus of
the stria terminalis, lateral hypothalamus, and paraventricular nucleus of the hypothalamus.
POMC exclusively projects to the dorsal motor nucleus of the vagus, reticular nucleus, nucleus
tractus solitaries, and lateral paracrachial nucleus (Cone 2005).
Other hormones that interact with the homeostatic pathways to affect feeding and body
weight are leptin, insulin, and ghrelin. Leptin is a hormone that is largely made by white adipose
tissue, and it decreases with hunger, increases with satiety, and inhibits feeding via receptors in
the ARC (Frederich et al 1995; Maffei et al 1995; Zhang et al 1994; Halaas et al 1995; Elmquist
et al 1998). Insulin increases with blood glucose levels (Polonsky et al 1988), and causes
hypophagia and weight loss within the CNS (McGowen et al 1992). Another peptide, ghrelin,
has orexigenic effects by activating AgRP/NPY neurons in the ARC while suppressing POMC
neural activity causing an overall increase in feeding and body weight (Seoane et al 2003;
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Cowley et al 2003; Wren 2000). Although, there is no one cause for food consumption, the
melanocortins and the peptides that affect them play a vital role in feeding. Furthermore, more
recent studies focus on how the ‘reward pathway’ contributes to rewarding aspects of feeding.
1.2

Mesolimbic dopamine pathway
There are certain areas within the brain that aid in motivation, learning, and pleasure.

These circuits are responsible for the hedonics, or pleasure, of food intake without affecting the
biological necessity of it. This occurs by changing the body’s response to salient environmental
stimuli causing food intake during a time of food availability rather than for energy needs. This
can result in a pleasurable experience. Evolutionarily speaking, without these pathways, animals
with full energy stores would not always eat when food was available, and once food availability
ran out, starvation could occur. One of the major hormones responsible for hedonic feeding is
dopamine. One of its many neuronal projections extends from the ventral tegmental area (VTA)
to the nucleus accumbens (NAc) and in combination with other projections is known as the
mesolimbic dopamine (DA) system.
Researchers unknowingly began looking into this ‘reward’ area of brain while researching
the cause for drug addiction. Drugs of abuse hijack these pathways which can be evolutionarily
assumed to be useful when finding food or water. Dr. Roy A. Wise was one of the original
researchers to focus his attention on the addiction phenomena. It was found that dopamine was
important for brain self-stimulation (Yeomans 1979), and that positive drug self-administration
regions of the midbrain overlapped with areas with a high density of dopaminergic cell bodies,
specifically in the VTA and substantia nigra (Corbett & Wise 1980; Bozarth & Wise 1981; Wise
1982). At this time dopamine was the neurotransmitter believed to cause these addictions (Wise
1982). Studies confirmed in rats and humans that dopamine related to addiction and drugs of
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abuse are found in the mesolimbic DA pathway, specifically from the VTA projecting to the
ventral striatum, which includes the NAc (Di Chiara & Imperato 1988; Koob 1992; McBride et
al 1999; Volkow et al 2004). Although, the VTA and NAc are often focused on, there are many
other areas involved in this system; these include the dorsal striatum (caudate putamen- CPu),
prefrontal cortex, and the amygdala. Research shows that it is the neurotransmitter dopamine in
the NAc that causes the behavior to seek the drug, or the reward, and that without dopamine, its
receptor, or its neurons, the self-administration or seeking behavior disappears (Ikemoto et al
1997; Roberts & Koob 1982). The result of increased dopamine levels from drugs of abuse
typically decreases dopamine-2 (D2) receptors (Volkow et al 2002). It is assumed that this
occurs as a reaction to an overabundance of dopamine; however, at this point it then requires
more dopamine, i.e. more drugs of abuse, to receive the same dopaminergic effect of a smaller
number of receptors. This phenomenon is thought to play a role in tolerance and addiction. This
is shown in self-administration studies where mice progressively increase the amount of cocaine
with similar resulting dopamine output (Ahmed et al 2002). The mechanisms by which dopamine
is increased depends of the specific drug of abuse (Ritz et al 1987).
Dopamine is often considered the major component of the mesolimbic DA system,
however, other transmitters play key roles in regulating the overall activity of this system.
Glutamate plays an important role in these pathways with afferent projections from areas such as
the hippocampus (O’Donnell & Grace 1995). GABA and endogenous opioids also affect the
activity of this system and compose a feedback loop within the reward pathway (Trigo et al
2010). In addition, acetylcholine (ACh), which has interneurons in the NAc and various other
projections throughout the system, is also an important regulator of the mesolimbic DA pathways
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(Mark et al 2011). The mesolimbic dopamine pathway has been studied for decades and is still
not completely understood.
1.3

Mesolimbic Dopamine System and Feeding
Dopamine is an important neurotransmitter with a wide range of physiological functions

including motivation, reward, and reinforcement, learning and memory, and motor control.
Conditions associated with abnormal dopamine show changes in feeding and body weight. For
example, dopamine-deficient (DD) mice are hypoactive, aphagic, and adipsic and will starve to
death without help (Zhou & Palmiter 1996). Certain atypical antipsychotics are dopamine-2 (D2)
receptor antagonists and are known to cause increased weight gain (Baptista et al 1990). D2
density has also been shown to be inversely proportional to the weight of obese patients
suggesting a potential role of D2 receptors in development of obesity (Wang et al 2002). One
study shows clozapine, a partial dopamine receptor antagonist, increases food intake in rats, and
a D2 receptor agonist reverses it (Kaur & Kulkarni 2002). Parkinsons disease is characterized by
dopamine cell death in the substantia nigra and its patients have lower body weight than their
healthy counterparts (Beyer et al 1995). Patients that are given more levodopa treatments, a
dopamine precursor, have a larger amount of weight loss suggesting the medication may be
responsible (Bachmann et al 2009).
As humans, we have the tendency to ‘finish our plate’ of food past the necessary need for
energy balance (Jansen et al 2003; Weingarten 1983). This alone suggests that some other
control systems other than basic energy needs are involved in feeding. Despite the important role
of the mesolimbic DA pathways in drugs of abuse, it is thought that these pathways were
originally designed to respond to naturally rewarding substances. Food and water increase
dopamine in the NAc and VTA similar to, but less than, drugs of abuse. This suggests that it is
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the overall reward that dopamine triggers, and is not specific to drugs (Hernandez & Hoebel
1988; Yoshida et al 1992). It has been shown that ‘addicted’ animals prefer highly-intense sugar
over cocaine suggesting that it is possible that food has the potency to be just as addicting as any
drug of abuse (Lenoir et al 2007). The mechanism for overeating shows similarities to drugs of
abuse. Obese patients have decreased D2 receptors similar to the decrease in drug addicts (Wang
et al 2001). In addition, patients who have undergone gastric bypass surgery have upregulated
D2 receptors, in theory, to try to restore the dopamine levels to previous pre-surgery ‘reward’
levels (Steele et al 2010). Similar findings have been shown in obese rats that are then placed on
a restricted feeding diet resulting in weight loss (Hamdi et al 1992). Rats on high fat diets are
less likely to experience ‘reward’ due to decreased self-stimulation, and presumably decreased
D2 receptors. When the D2 receptors are knocked down, feeding dramatically increases
supporting the theory that dopamine is what is responsible for giving the ‘rewarding’ feeling. It
is also possible that without these receptors animals will consume drugs or food to try to receive
the same dopamine stimulation. In evolution theory, these reward pathways were likely put in
place for species necessities such as food, water, and reproduction; however, drugs of abuse use
these pathways to cause their own rewarding effects. Although the reward pathway can
independently affect feeding, its interactions with other pathways are just as important.
1.4

Reward and the dorsal striatum
Although the ventral striatum/NAc gets a lot of attention in the mesolimbic DA pathway,

the dorsal striatum is a key target for DA output as well. The dorsal striatum which is composed
of the caudate putamen (CPu) is another key area of interest. Its inputs include the cortex,
thalamus, and the mesolimbic DA neurons which are similar areas to the ventral striatum
pathways (VTA to NAc). The NAc has dopaminergic innervations via the VTA whereas the CPu
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has domaminergic innervations via the substantia nigra. These DA neurons have been
characteristically associated with motor function and their deficiency with the neuromuscular
disorder Parkinsons Disease (PD) (Chase et al 1996). PD patients have symptoms that include
hypophagia; however, this is attributed to the associated dysphagia and depression. The CPu’s
effects on reward were shown as far back as the 80s (Hikosaka et al 1989). Research also
associates the CPu with learning, which is an important component of reward (Jog et al 1999;
Packard & White 1990).
While the CPu has known effects in drugs, learning, and PD, recent research has indicated
importance in feeding. Szczypka et al restored DA in dopamine deficient (DD)-mice only in the
CPu. This resulted in mice regaining the motivation to eat and ability to maintain an adequate
sustainable body weight which is not possible in DD-mice (Szczypka et al 2001). In addition, it
has been shown that dopamine increases in relation to drinking in rats in the NAc as well as the
CPu (Young et al 1992). This suggests that it is possible that motivation and learning, which are
components of addiction and rewarding behavior, to eat or drink is not solely contained within
the ventral striatum and its efferent projections from the VTA. The ‘reward’ circuits may lie
within the ventral as well as dorsal striatum. This also suggests that the hypophagia associated
with Parkinsons may be due to the dopamine or melanocortin neuronal changes in the dorsal
striatum.
1.5

Mesolimbic and homeostatic feeding pathway interactions
While most research has focused on the role of homeostatic or hedonic pathways of food

intake control independent of each other, it is clear that there are important interactions between
these pathways. Although this is thought of as a new area of study, researchers have been
investigating this connection for decades. It has been shown that animals will lever-press for
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heroine injections into the hypothalamus, a role traditionally thought of in the mesolimbic DA
pathway (Gerber et al 1981). In addition, excitation of the lateral hypothalamus via the medial
forebrain bundle causes the same dopamine release in the NAc independent of the VTA
(Hernandez & Hoebel 1988; 1988). By 1992 evidence of a direct link between the NAc shell and
the lateral hypothalamus was well documented (Heimer et al 1991; Zahm & Brog 1992), and it
was known that the NAc has role in feeding behavior (Salamone 1994).
The mechanism of how these two pathways interact and how they affect food intake is still
developing. Rada et al found glutamate levels in the lateral hypothalamus and the NAc changed
in response to food intake suggesting not only do these areas share pathways, but that they also
aid in the control of feeding (Rada et al 1997). Also, NAc-induced feeding could be attenuated
with GABA agonist injections into the lateral hypothalamus (Maldonado-Irizarry et al 1995). In
addition to the NAc the hypothalamus has been shown to have connections to the VTA.
Retrograde tracing injected into the lateral hypothalamus shows strong afferents in the VTA,
NAc shell, and many other areas (Duva et al 2005). Orexin, an orexigenic neuropeptide, has been
shown to have projections from the lateral hypothalamus to the VTA (Fadel & Deutch 2002).
Also, orexin injected into the VTA causes firing, and orexin projections to the VTA are required
for morphine-related conditioned place preference (Korotkova et al 2003; Narita et al 2006).
Recent studies have shown that orexin signaling in the VTA is required for opioid-induced food
intake in the NAc suggesting not only a connection between the lateral hypothalamus and the
VTA, but a possible relationship to rewarding food intake (Zheng et al 2007). In addition to
orexin, melanin-concentrating hormone (MCH), another orexigenic neuropeptide, also has
projections from the lateral hypothalamus to the mesolimbic DA pathway (Bittencourt et al
1992) with many receptors in the VTA and NAc specifically (Hervieu et al 2000). Smith et al
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showed that MCH-1 receptor knockout mice, characterized by hyperactivity and hypophagia,
have increased dopamine in the VTA as well as the NAc further suggesting a functional
association between these two areas (Smith et al 2005).
In addition to the neuronal connection between the VTA, NAc, and lateral hypothalamus,
dopamine neurons in the VTA have receptors for important feeding relevant hormones similar to
the ARC. Leptin, insulin, and ghrelin not only affect feeding via the homeostatic pathways, but
they also have effects on dopamine within the mesolimbic DA system to affect feeding. Leptin
when injected in the ventricles decreases feeding-evoked dopamine release in the NAc (Krugel et
al 2003). Insulin receptors have also been found in the VTA dopaminergic neurons, (Pardini et al
2006; Figlewicz et al 2003) and intraventricular insulin was shown to reduce the self-stimulation
of sucrose (Figlewicz et al 2006). Ghrelin increases dopamine firing in the VTA and decreases
inhibitory firing and as a result causes food intake (Abizaid et al 2006; Naleid et al 2005). Figure
3 created by RD Palmiter shows the different hormones and neuropeptides that have been shown
to affect dopaminergic neurons in the VTA (Palmiter 2001).

Figure 3. Neuropeptides that affect dopamine neurons
GABA, leptin, and insulin have been shown to have inhibitory receptors on DA neurons in the
VTA, while ghrelin, orexin, and glutamate have been shown to have excitatory receptors in the
VTA (Palmiter 2001).
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1.6

Mesolimbic dopamine pathway and melanocortin interactions
In addition to leptin’s, insulin’s, and ghrelin’s interaction with dopaminergic pathways,

there is also evidence indicating melanocortin involvement within the VTA and the mesolimbic
DA system. MC4R mRNA has been found in the VTA, NAc, and CPu, and the MC3R has been
found extensively in the VTA (Kishi et al 2003; Liu et al 2003; Rosseli-Rehfuss et al 1993). αMSH injections in the VTA have been shown to increase dopamine turnover and grooming in
rats, a typically melanocortin characterization, via the MC4R (Klusa et al 1998; Lindblom et al
2001). In addition, γ1-MSH injections into the VTA increase dopamine and its metabolites in the
NAc (Jansone et al 2004). In 1986, it was shown that α-MSH injected into the ventricles or
substantia nigra causes changes in dopamine in the caudate putamen (Torre & Celis 1986). Davis
et al showed that centrally administered AgRP, a melanocortin antagonist, increased dopamine
firing in the midbrain with associated dopamine turnover in the prefrontal cortex, a known
projection site of mesolimbic DA neurons (Davis et al 2011).
Many studies looking at drugs of abuse have also linked melanocortins with the
mesolimbic DA pathway. Alvaro et al showed that morphine down-regulated MC4R in the NAc
as well as the CPu (1996). An exogenous melanocortin receptor agonist was shown to cause an
increase in rewarding effects of amphetamines in the lateral hypothalamus (Cabeza de Vaca et al
2002). Similarly, an exogenous melanocortin receptor antagonist caused a decreased in
rewarding effects of cocaine in the NAc (Hsu et al 2005, 2009). Here, the term ‘rewarding
effects’ refers to the perceived reward received from drugs of abuse and the reinforcing
motivation to seek said drug. In addition, POMC mRNA was shown to decrease in response to
morphine (Bronstein et al 1990). This building research shows that the melanocortins interact
with mesolimbic DA system to affect responses to various drugs of abuse.

14
It seems clear that the melanocortins interact with the mesolimbic DA pathway for some
behaviors; however, there is little research referring to this interaction and its direct effects on
feeding. Xenakis and Sclafani showed that a dopamine receptor antagonist suppressed sucrose
preference (1981). In addition, melanocortin agonists or NPY antagonists can inhibit opioid
induced feeding in the NAc (Zheng et al 2010). These findings suggest that melanocortins and
AgRP/NPY have projections as well as possible feeding related interactions with the NAc.
Figure 4 shows the theorized mechanism for how the homeostatic pathway interacts with the
reward pathway (Palmiter 2007). In addition, recent studies have shown that melanocortin
agonists injected directly into the VTA cause a decrease in food intake (Roseberry, personal
communication), however, more information is required to fully understand the role
melanocortins play in the mesolimbic DA system to affect feeding.
1.7

Research Goals
I will create short-hairpin RNAs (shRNAs) that target MC3R and MC4R separately. These

shRNAs will be used in in vitro co-transfections with their target receptors to examine
knockdown efficiencies of each shRNA.
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Figure 4. A sample of the known relationships between the homeostatic and reward
pathways
Leptin and insulin act on the ARC on POMC/CART and AgRP/NPY neurons to decrease
feeding while ghrelin acts on these areas to increase feeding in the homeostatic pathway.
POMC/CART and AgRP/NPY neurons both have projections to many similar locations
including the paraventricular nucleus and the lateral hypothalamus. Orexin neurons project from
the lateral hypothalamus to the VTA of the reward pathway. The reward pathway consists of DA
and GABA projections to the NAc. Leptin, insulin, and ghrelin also can act in the VTA (Palmiter
2007).

2
2.1

METHODS/EXPERIMENTAL PROTOCOL
Creation of shRNA targeting the MC3R and MC4R
Three 24 base pair short hairpin RNAs (shRNAs) were designed to target the MC3R and

three to target the MC4R The shRNAs were created using previously developed methods
(Hommel et al 2003) and BLASTed to ensure specificity. The sequences of each shRNA can be
seen in Table 1.
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Table 1. Targeted mRNA sequences used to create pAAV short-hairpins

mRNA sequence
MC3R
sh1 TCCCTGACCTTGGAGGACCAATTC
sh2 TGCGGCGTGATGTTCATCGTCTAC
sh3 ACACGGCGCACTTCAACACCTACC
MC4R
sh1 TCATAAGCCTGTTGGAGAACATTC
sh2 GCAGTGGACAGGTATTTCACTATC
sh3 CTACATCTCTTGTCCTCAGAATCC
CONTROL
CGGAATTTAGAAACCCGGCTCCAA

The control mRNA sequence was created and tested previously and has no known target
(Hommel et al 2003). Effective shRNAs were created by using a 10 nucleotide hairpin loop
(CTTCCTGTCA) to join the antisense shRNA to the corresponding sense strand sequence as
shown in Figure 5. The shRNAs were cloned into a pAAV vector using standard methods to be
used for future creation of adeno-associated viruses (AAVs). The AAV shRNA constructs will
express the shRNAs under control of the mU6 promoter, and also contain GFP under the control
of the CMV promoter to allow for high level expression of both the shRNA and the marker GFP
as seen in Figure 6.
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Figure 5. Schematic of short-hairpin creation used in RNAi
The sense strand is the 24 bp target RNA sequence followed by a hairpin loop, the antisense
strand, followed by a terminating poly T tail.

Figure 6. Design of AAV shRNAs
Image shows that GFP is controlled by a CMV promoter while the shRNA is controlled by a
mU6 promoter

2.2

ptdTomato-MC3/4R creation
Gene fusion constructs were created containing the MC3R or MC4R cDNA fused to the C-

terminus of the tdTomato fluorescent protein in the ptdTomato-C1 vector (Clontech
Laboratories) using EcoRI and XbaI restriction enzymes and standard molecular biology
techniques. These fusion constructs will be used for in vitro studies to test shRNA ability to
suppress tdTomatoMC3/4R. The MC4R was received as a generous gift from Dr. Xin-Yun Lu,
University of Texas Health Science Center at San Antonio, and the MC3R was synthesized de
novo by GenScript. The MC3/4R portion of the tdTomatoMC3/4R fusion constructs are not in
frame so no mature MC3/4R protein is attached to the C-terminus of the functional tdTomato
protein; however, there is full mRNA expression which allows for targeting of the tdTomato
MC3/4 R mRNA by the shRNAs.
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2.3

shRNA testing in vitro
The pAAv-shRNA constructs, as described in 2.1, were co-transfected with the

tdTomatoMC3/4R fusion constructs, as described in 2.2, into HEK-293 cells to determine the
most effective shRNA to be used for in vivo experimentation. The pAAV-shRNA (5 μg) and
ptdTomatoMC3/4R (1 μg) DNAs were co-transfected into HEK-293 cells using standard
calcium-phosphate methods (Roseberry et al 2001). Each shRNA in vitro experiment was
Table 2. Experimental co-tranfections into HEK-293 cells
The pAAV-shRNA co-transfected with its target receptor, as seen on the left, are used to test
knockdown effectiveness, while the pAAV-shRNA co-transfected with a control target, as seen
on the right, are used to test knockdown specificity of the shRNA.
ptdTomatoMC3R + pAAV-MC3Rsh1
ptdTomatoMC3R + pAAV-MC3Rsh2
ptdTomatoMC3R + pAAV-MC3Rsh3
ptdTomatoMC3R + pAAV-shControl
ptdTomatoMC3R + pAAV

ptdTomatoMC3R + pAAV-MC4Rsh1
ptdTomatoMC3R + pAAV-MC4Rsh2
ptdTomatoMC3R + pAAV-MC4Rsh3
ptdTomatoMC3R + pAAV
ptdTomatoMC3R + pAAV-MC3Rsh2

ptdTomato-MC4R + pAAV-MC4Rsh1
ptdTomato-MC4R + pAAV-MC4Rsh2
ptdTomato-MC4R + pAAV-MC4Rsh3
ptdTomato-MC4R + pAAV-shControl
ptdTomato-MC4R + pAAV

ptdTomatoMC4R + pAAV-MC3Rsh1
ptdTomatoMC4R + pAAV-MC3Rsh2
ptdTomatoMC4R + pAAV-MC3Rsh3
ptdTomatoMC4R + pAAV
ptdTomatoMC4R + pAAV-MC4Rsh2

performed 3-4 times and included an empty pAAV and a pAAV control shRNA as internal
controls. Cells were plated to polylysine covered cover-slips one day post-transfection and were
then fixed with methanol/acetone and mounted to slides three days post-transfection.
As seen in Table 2, specificity was tested by completing co-transfections with
MC3RshRNAs with tdTomatoMC4R and MC4RshRNAs with the tdTomatoMC4R. These
experiments also had an empty pAAV vector as a negative control and a receptor-specific shorthairpin as a positive control.
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2.4

Data Analysis and Statistics
Slides containing the transfected cells were viewed using a Nikon E800 upright microscope.

Slides were randomly sampled and approximately ten images were taken per transfection. Image
acquisition parameters were the same for all treatments in each individual experiment. Images
were quantified using ImageJ software (National Institute of Health, Bethesda, MD). Positive
cells were selected using brightness thresholds and cell counter functions, and all measurements
were confirmed by experimenter. Paired t-tests were used to compare the number of GFP and
tdTomato positive cells for each treatment. One-way ANOVA with Holm-Sidak post-hoc tests
were used to compare the level of tdTomato knockdown observed for each pAAV construct.

3

RESULTS
Three pAAV-shRNAs were created targeting the MC3R or MC4R, and each shRNA was

tested in vitro for its effectiveness in knocking down MC3R or MC4R. The knockdown was
measured by comparing the number of cells expressing tdTomato to the number of cells
expressing GFP, which is expressed by pAAV, and is used to mark all transfected cells. The
MC3/4Rs are fused to the C-terminus of the tdTomato and will produce one mRNA that will be
targeted by the shRNAs. In a successful knockdown, the shRNAs, co-expressed with GFP, will
knockdown the tdTomatoMC3/4R fusion reducing tdTomato fluorescence. In an unsuccessful
knockdown, both GFP and tdTomato fluorescence will be present. As mentioned previously, the
MC3/4R is not in frame with the tdTomato, and no functional receptor protein will be created;
however, these experiments will remain unaffected because the tdTomato fluorescent protein
will still be expressed. In each experiment, an empty pAAV vector and a scrambled control
short-hairpin were co-tranfected with each tdTomato-receptor as negative controls.
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Initially, the MC3R shRNAs were tested (Figure 7-9). The three shRNAs targeting MC3R
significantly decreased tdTomatoMC3R expression (Figure 7-9) to varying degrees. MC3Rsh2
had the greatest tdTomato knockdown with 85.5% followed by MC3Rsh3 with 78.9% and
MC3Rsh1 with 70.8% (Figure 9). Finally, as expected, the control shRNA had no effect on
tdTomatoMC3R expression (Figure 7-9).
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Figure 7. Sample images showing effectiveness of the MC3R shRNAs on tdTomatoMC3R
expression
Green cells indicate GFP expressed by the pAAV-shRNA, and red cells indicate
tdTomatoMC3R expression. A decrease in the number of red cells as compared to green cells is
indicative of the ability of the shRNA to block expression of the tdTomato-MC3R.
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Figure 8. MC3R shRNAs decrease expression of tdTomatoMC3R in HEK-293 cells
Total number of GFP-positive (Light grey) and tdTomato-positive cells (Dark grey) following
co-transfection of the shRNAs with the tdTomatoMC3R. ‘Empty’ refers to pAAV vector with
no shRNA. *p < 0.05; n=4.
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Figure 9. Extent of knockdown of the tdTomatoMC3R by the MC3R shRNAs
All three shRNAs decreased expression of tdTomatoMC3R compared to empty pAAV and
shControl. *p < 0.001 compared to both empty pAAV and shControl; n=4.
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Next, MC4R shRNAs were tested to investigate their ability to block expression of the
tdTomatoMC4R As with the MC3R, all MC4R shRNAs decreased tdTomato expression to
varying degrees (Figure 10-12). MC4Rsh3 was the most effective (90.4% knockdown) followed
by MC4Rsh2 (88.6% knockdown) and MC4Rsh1 (73.7% knockdown). Finally, similar to
MC3R, the control shRNA had no effect on expression of the tdTomatoMC4R protein (Figure
10-12).
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Figure 10. Sample images showing effectiveness of the MC4R shRNAs on tdTomatoMC4R
expression
Green indicates GFP expressed by the pAAV-shRNA construct, and red indicates tdTomato
expression. A decrease in the number of red cells as compared to the green cells is indicative of
the ability of the shRNA to block expression of the tdTomatoMC4R.

25

400

Total number of cells

350
300
250
GFP

200

tdTomato

150
100

*
*

50

*

0
Empty

shControl

MC4Rsh1

MC4Rsh2

MC4Rsh3

Figure 11. MC4R shRNAs decrease expression of tdTomatoMC4R in HEK-293 cells
Total number of GFP-positive (Light grey) and tdTomato-positive cells (Dark grey) following
co-transfection of the shRNAs with the tdTomatoMC4R. ‘Empty’ refers to pAAV vector with
no shRNA. * p< 0.05; n=3.
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Figure 12. Extent of knockdown of the tdTomatoMC4R by the MC4R shRNAs
All three shRNAs decreased expression of tdTomatoMC4R compared to empty pAAV and
shControl. * p< 0.001 compared to both empty pAAV and shControl; n=3.
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Experiments were also performed to test the specificity of the shRNAs. In these experiments
the ability of the MC3R shRNAs to affect expression of the tdTomatoMC4R was tested, as was
the ability of the MC4R shRNAs to affect expression of the tdTomatoMC3R. As shown by
Figures 13-16, none of the shRNAs affected expression of the non-targeted receptor. This
suggests that all six of the shRNAs are specific to their own receptor. Overall, pAAV-MC3Rsh2
and pAAV-MC4Rsh3 had the greatest tdTomato knockdown, and therefore will be used for
future in vivo experimentation.

Figure 13. Sample images showing no MC3Rsh2 effect on tdTomatoMC4R
Green indicates GFP expressed by the pAAV-shRNA construct, and red indicates tdTomato
expression. Images suggest MC3Rsh2 has no knockdown on tdTomatoMC4R and is specific to
its target receptor, MC3R.
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Figure 14. MC3R shRNAs do not affect expression of tdTomatoMC4R
Total number of GFP-positive (Light grey) and tdTomato-positive cells (Dark grey) following
co-transfection of the MC3R shRNAs with the tdTomato-MC4R. ‘Empty’ refers to pAAV
vector with no shRNA. pAAV-MC4Rsh2 was included as a positive control; n=2.

Figure 15. Sample images showing no MC4Rsh3 effect on tdTomatoMC3R
Green indicates GFP expressed by the pAAV-shRNA construct, and red indicates tdTomato
expression. Images suggest MC4Rsh3 has no knockdown on tdTomatoMC3R and is specific to
its target receptor, MC4R.
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Figure 16. MC4R shRNAs do not affect expression of tdTomatoMC3R
Total number of GFP-positive (Light grey) and tdTomato-positive cells (Dark grey) following
co-transfection of the MC4R shRNAs with the tdTomato-MC3R. ‘Empty’ refers to pAAV vector
with no shRNA.. pAAV-MC3Rsh2 was included a positive control; n=2.

4

DISCUSSION
The mesolimbic DA pathway has been shown to have physiological interactions with

melanocortins (Klusa et al 1998; Alvaro et al 1996; Bronstein et al 1990) as well as melanocortin
receptor mRNA (Roselli-Rehfuss et al 1993; Kishi et al 2003; Liu et al 2003). This system has
also been shown to affect feeding via similar mechanisms (Maldonado-Irizarry et al 1995; Wang
et al 2001; Salamone 1994). Therefore, this pathway acts as a place of interest for better
understanding melanocortin’s role in feeding behaviors. Previous studies have used a variety of
techniques (MC4R-null animals, RNAi , cell-specific receptor knockouts) to show that
melanocortins affect food intake within the hypothalamus (Huszar et al 1997; Balthasar et al
2005; Garza et al 2008). None of these relatively new techniques, however, have been used to
understand whether melanocortins affect feeding through the mesolimbic DA pathway.
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In these studies, shRNAs targeting the MC3R and MC4R were designed, tested, and
resulting in varying degrees of successful knockdown. The shRNAs with the highest knockdown
were pAAV-MC3Rsh2 with 85.5% knockdown (Figure 9) and pAAV-MC4Rsh3 with 90.4%
knockdown (Figure 12), thus making them the chosen shRNAs for future use in rats in vivo.
pAAV-MC4Rsh1 is the only short-hairpin created that could be used in rat as well as
mouse animals models because of a shared coding region, acacggcccatttcaacacctacc, found at
base pair 167 in the rat. The option of using two different animal models to investigate
melanocortin’s role in mesolimbic DA pathways could add to the evidence of a conserved
pathway between species.
Previous studies have found that the U6 promoter in vitro knockdown was found to be
~80% (Makinen et al 2006). Another similar study using the U6 promoter to target MC4R in
vitro found their knockdown ranged from 86 to 94% over three different short-hairpins (Garza et
al 2008). Therefore, the 85.4 and 90.4% knockdown for MC3R and MC4R respectively seems to
be an appropriate knockdown level in vitro. Therefore, these shRNAs would be suitable
candidates for future in vivo testing. The expression of GFP and shRNA is under the control of
different promoter regions (U6 expresses shRNA; CMV expresses GFP), and effective
knockdown still occurs as seen in current and previous studies using similar shRNA constructs
(Hommel et al 2003).
The shRNA constructs have the potential to answer many questions about the
connections between melanocortins and the mesolimbic DA pathways, and their roles in a
number of behaviors including food intake. Based on important roles of both the mesolimbic DA
system and melanocortins in feeding, a likely first set of experiments would be to examine
whether MC3R or MC4Rs in the mesolimbic DA system play a role in feeding. MC3R mRNA is
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found in high levels in the VTA, while MC4R mRNA is found in low levels in the VTA,
moderate levels in the NAc, and high levels in the CPu (Roselli-Rehfuss et al 1993; Kishi et al
2003; Liu et al 2003). In addition to the mRNA, it is known that melanocortins have functional
or physiological effects within the same regions (Klusa et al 1998; Lindblom et al 2001; Jansone
et al 2004; Alvaro et al 1996; Hsu et al 2005, 2009). Therefore, the VTA, NAc, and CPu are all
regions of interest that could be examined. While, it is known that dopamine can affect baseline
feeding, there is evidence to suggest that it affects rewarding feeding as well. Highly palatable
food causes increased c fos in the VTA (Park & Carr 1998), and inactivation of the NAc causes
increased preference for high-fat and high-sugar foods (Zhang & Kelley 1997). Thus, normal
feeding as well as reward-related feeding, such as high fat and high sugar foods, are logical areas
to be examined.
In addition to feeding-related studies, melanocortins have also been shown to have drugrelated interactions in the mesolimbic DA system (Alvaro et al 1996; Hsu et al 2005; Bronstein
et al 1990). Thus, melanocortin shRNAs could also be used to investigate drug-related behaviors,
such as locomotion, conditioned place preference, and self-administration within the mesolimbic
DA system.
There are multiple methods that could be used to investigate melanocortin effects within
the mesolimbic DA system; however, RNA interference was the best possible for the questions
addressed in this study. Genetic knockout animals, in which knockout either occurs throughout
the brain or in specific cells, are often used to investigate similar questions. It is currently
unknown, however, which neurons MC3/4Rs are located on, and thus is a disadvantage because
it cannot be used to target overall regions, i.e. VTA. Another possible method could have been
agonist or antagonist microinjections. Although this method can target specific regions, it is
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limited by the number of microinjections allotted to one animal. This limits not only the length
of the study (acute vs. chronic), but the varying types of behaviors that can be examined within
one animal. RNA interference is not without downfall however. shRNAs are not likely to create
100% receptor knockdown. Therefore the full behavioral effects of that receptor cannot be seen.
In these studies, the ability to target a specific area over a longer period of time was important,
and thus RNA interference was chosen as the methodology.
In summary, these highly effective shRNAs can be used to target various regions of the
mesolimbic DA pathway as well as to examine various behavioral effects within these regions.
These studies will allow for investigation of melanocortin effects within the mesolimbic DA
system and for further characterization of melanocortin function in respect to rewarding feeding
on high-fat foods as well as high-sugar foods.
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